
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals is expected to do well in 2026 and beyond, with potential growth in its Rare Disease and Brands businesses, as well as its Generics portfolio. Additionally, expected improvements in revenue from their Purified Cortrophin Gel, ILUVIEN, and YUTIQ products, as well as an overall increase in revenue, suggest a positive outlook for the company. However, there are potential risks such as unforeseen setbacks and challenges with the Alimera integration or in executing deals, and worsening pricing and competitive pressures in the generics industry.
Bears say
ANI Pharmaceuticals is experiencing a decrease in sales guidance for their key product, Cortrophin, due to weaker-than-expected performance in the first half of the year. Additionally, while prescription volumes for Cortrophin have reached all-time highs, this has not translated into significant revenue growth, leading to investor hesitation. However, the company's strong presence in the generics market and their expanding sales force present a potential for long-term growth.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares